EGFR and non-small cell lung carcinoma: Based on the DFS and OS data, osimertinib received authorization by the FDA and EMA as an adjuvant treatment for patients with resected stage IB to IIIA NSCLC and common sensitizing EGFR mutations (i.e., deletion of 19 exon or L858R).